Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer

Table 1 Patient characteristics

		n (%)
Clinical stage1	T1c	10 (45.5)
	T2a	4 (18.2)
	T2b	4 (18.2)
	T2c	1 (4.5)
	T3	1 (4.5)
	T3a	2 (9.1)
Biopsy Gleason score	0 + 0	1 (4.5)
	3 + 3	3 (13.6)
	3 + 4	5 (22.7)
	4 + 3	5 (22.7)
	4 + 4	4 (18.2)
	4 + 5	4 (18.2)
Pathology stage	pT2a	3 (13.6)
	pT2b	5 (22.7)
	pT3a	7 (31.8)
	pT3b	6 (27.3)
	pT4	1 (4.5)
Pathology Gleason score	3 + 3	1 (4.5)
	3 + 4	8 (36.4)
	4 + 3	4 (18.2)
	4 + 4	4 (18.2)
	4 + 5	3 (13.6)
	5 + 4	1 (4.5)
	Not Graded2	1 (4.5)
Prior radiation treatment	EBRT	11 (50)
	Untreated	11 (50)

¹Clinical stage was determined prior to primary or salvage surgery;

²One index tumor was not graded due to treatment effect. EBRT: External beam radiation therapy.

Table 2 Spearman correlations between proton magnetic resonance spectroscopic imaging and ¹⁸F-fluorodeoxyglucose data (n = 22)

1H-MRSI	18F-FDG	Rho (ρ)	P-value
CC/Cmax	SUVmax	-0.281	0.21
	SUVmean	-0.101	0.66
CC/Cmean	SUVmax	-0.362	0.10
	SUVmean	-0.158	0.48
Total # Voxels	SUVmax	0.2565	0.25
	SUVmean	0.2783	0.21

¹H-MRSI: Proton magnetic resonance spectroscopic imaging;

¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose.

Table 3 Spearman correlations between proton magnetic resonance spectroscopic imaging and ¹⁸F-fluorodeoxyglucose data and surgical Gleason score (n = 22)

	With Gleason score
18F-FDG/1H-MRSI	Rho (ρ)	P-value
CC/Cmax	0.2165	0.35
CC/Cmean	0.0624	0.79
Total # Voxels	0.5493	0.0099
SUVmean	0.3225	0.15
SUVmax	0.4584	0.0366

¹H-MRSI: Proton magnetic resonance spectroscopic imaging;

¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose.